Atossa Genetics reports Q2 EPS (80c) vs. ($5.08) a year ago as restated.
Steven Quay, Atossa Genetics' President and CEO commented, "During the quarter we were very pleased to have achieved our primary endpoint in our Phase 2 trial of topical Endoxifen to reduce mammographic breast density. We are now focusing our efforts on the oral formulation of Endoxifen and are developing a modified-release oral tablet which is being tested in a Phase 1 study and that we plan to use in a Phase 2 study to reduce MBD. The Phase 2 study is scheduled to start in the fourth quarter and should be completed by mid-2020. We completed the quarter with $17.1M in cash, which will enable us to continue to make clinical progress with our programs."
|Printer friendly Cite/link Email Feedback|
|Article Type:||Financial report|
|Date:||Aug 13, 2019|
|Previous Article:||Spotify in talks with Apple over Siri voice commands, Information reports.|
|Next Article:||CBS, Viacom to combine in all-stock merger to create ViacomCBS.|